clinician – Page 103 – Communicable Diseases Research

Hematological features of persons with COVID-19

Research

Published on 2020-06-112022-10-05
Journal: Leukemia [Category] SARS, 치료기술,

Predictors of fatality including radiographic findings in adults with COVID-19

Research

Published on 2020-06-112022-10-28
Journal: Respiratory Research [Category] COVID-19,

[키워드] acute respiratory syndrome Admission age Analysis approved clinician Confirmed coronavirus coronavirus disease COVID-19 defined died discharged early stage elevated elevated lactate dehydrogenase fatality help hospital Hospitalized identify independent risk factor involved laboratory-confirmed LDH lobes lung lobe Lymphocyte count median age non-survivor Older Patient patients poor prognosis positive RT-PCR predictor quarantine Radiographic Radiographic findings Radiologists Regression model remained reported Result risk factor SARS-CoV-2 SARS-COV-2 infection severity significantly subset Survivors throat-swab specimens Tongji Hospital variables with COVID-19 Wuhan, China
[DOI] 10.1186/s12931-020-01411-2 PMC 바로가기 [Article Type] Research

Prospects of Replication-Deficient Adenovirus Based Vaccine Development against SARS-CoV-2

Brief Report

Published on 2020-06-102022-10-28
Journal: Vaccines [Category] COVID-19,

A Guide for Oncologic Patient Management during Covid-19 Pandemic: The Initial Experience of an Italian Oncologic Hub with Exemplificative Focus on Uro-Oncologic Patients

Commentary

Published on 2020-06-102022-10-31
Journal: Cancers [Category] COVID-19,

Treatment outcomes and prognostic factors for non- malignancy associated secondary hemophagocytic lymphohistiocytosis in children

Research Article

Published on 2020-06-092022-10-28
Journal: BMC Pediatrics [Category] Coronavirus, SARS,

[키워드] albumin Allogeneic Analysis Autoimmune disease calculated cause cell transplantation children clinician Dexamethasone Diagnosis Disease progression EBV excluded Factor hazard ratio HCT hemoglobin hemophagocytic lymphohistiocytosis HLH Hyperinflammatory syndrome identify immunodeficiency Infection malignancy median age medical record outcome parameter Patient patients Pediatric patient Platelet Predictive prognostic Prognostic factor Prognostic factor, risk stratification regimen Result risk secondary hemophagocytic lymphohistiocytosis survival survival analysis Therapies therapy Treatment Treatment response virus
[DOI] 10.1186/s12887-020-02178-7 PMC 바로가기 [Article Type] Research Article

Immune-Inflammatory Parameters in COVID-19 Cases: A Systematic Review and Meta-Analysis

Medicine

Published on 2020-06-092022-10-31
Journal: Frontiers in Medicine [Category] COVID-19,

[키워드] addition analyzed available data CD4+ T lymphocyte CD8+ characterized China Clinical severity clinician CNKI Complete coronavirus disease COVID-19 COVID-19 patient CRP demonstrated Disease progression distress early stage erythrocyte sedimentation rate ESR Final Health help identify IL-6 Immune status Immune-inflammatory parameters Inflammation Internet lymphocyte marker Meta-analysis Mortality neutrophil neutrophil counts neutrophil-lymphocyte ratio NLR non-severe patients outbreak parameters Patient patients patients with COVID-19 PCT predict procalcitonin progression Protein review risk factor Severe patient severity statistically Subtypes Surveillance syndrome systemic inflammatory response T lymphocyte the disease was performed WBC Web of Science White blood cell
[DOI] 10.3389/fmed.2020.00301 PMC 바로가기 [Article Type] Medicine

Effect of Cancer on Clinical Outcomes of Patients With COVID-19: A Meta-Analysis of Patient Data

Review Articles

Published on 2020-06-082022-10-31
Journal: JCO Global Oncology [Category] COVID-19, SARS,

Evaluating the efficacy and safety of human anti-SARS-CoV-2 convalescent plasma in severely ill adults with COVID-19: A structured summary of a study protocol for a randomized controlled trial

Letter

Published on 2020-06-082022-10-29
Journal: Trials [Category] COVID-19, SARS,

[키워드] activity adverse event allergic reaction anti-SARS-CoV-2 anti-SARS-CoV-2 antibody Anti-SARS-CoV-2 plasma Anti-viral blinded Blood blood product center Chest radiography Clinical improvement Clinical outcome clinical status clinical trial clinician collected Columbia University control arm convalescent plasma coronavirus COVID-19 COVID-19 symptom criteria cumulative Date defined Dilution discharge dissemination Donor ECMO Efficacy Efficacy and safety element evaluate Evaluating Evidence extracorporeal membrane oxygenation hazard hazard ratio HBV HCV HIV hospital Hospitalized hospitalized patient IgA deficiency immune incidence include Infection Influenza Invasive mechanical ventilation mechanical ventilation multi-organ failure nasopharyngeal Nasopharyngeal swab New York Non-invasive number objective occur oropharyngeal swab outcome oxygen saturation participant Participants patients hospitalized PCR test PCR-negative per-protocol analysis peripheral capillary plasma platform post-hoc analysis Pregnancy primary endpoint protocol randomization Randomized Randomized controlled trial randomized, controlled trial randomly permuted block receive Registered Remdesivir requiring high-flow oxygen requiring supplemental oxygen Research Respiratory failure retrospective Ritonavir safety endpoint Sample size SARS-CoV-2 SARS-CoV-2 antibody SARS-COV-2 infection screened Serious Adverse Event seven-point ordinal scale severe COVID-19 severe SARS-CoV-2 severely ill adult single-center spike trimer SpO2 status study participant study period Study protocol supplemental oxygen tested therapy transfused Treatment treatment for COVID-19 Trial undergo USA Version Volunteer Wald test website with COVID-19 World Health Organization ZIKV
[DOI] 10.1186/s13063-020-04422-y PMC 바로가기 [Article Type] Letter

Association of Inpatient Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers With Mortality Among Patients With Hypertension Hospitalized With COVID-19

10010

Published on 2020-06-052022-10-31
Journal: Circulation research [Category] COVID-19,

[키워드] ACEi adjusted hazard ratio age all-cause mortality Analysis Angiotensin II angiotensin II receptor blocker Angiotensin-converting enzyme angiotensin-converting enzyme inhibitor antihypertensive drugs ARB association blocker blockers China clinician Comorbidities confounders content coronavirus coronavirus disease COVID-19 COVID-19 mortality Cox model decreased mortality demonstrated determine diagnosed with COVID-19 Digital Gender hospital Hospitalized hospitalized patient hypertension In-hospital increased mortality indicated inhibitors Inpatient Inpatients Interpretation lower risk median age medications men Patient patients with COVID-19 random effect receive receptor retrospective risk unlikely variable while with COVID-19
[DOI] 10.1161/CIRCRESAHA.120.317134 PMC 바로가기 [Article Type] 10010

Disentangling the Hypothesis of Host Dysosmia and SARS-CoV-2: The Bait Symptom That Hides Neglected Neurophysiological Routes

Physiology

Published on 2020-06-052022-10-31
Journal: Frontiers in Physiology [Category] COVID-19,

[키워드] Affect arise Blood Brain Central nervous system clinician consequence coronavirus COVID-19 death dysosmia effort excluded healthcare healthy Hospitalized Host host pathogen interactions human host hypoxia individuals infection with SARS-CoV-2 infections local inflammation lung nasal Neglected nervous system Neuroinvasive Neurological symptoms neuronal Neuropsychiatric occur olfactory olfactory bulb other coronavirus other coronaviruses outbreak pandemic Patient Premature proliferation public health researcher Respiratory failure route SARS-CoV-2 shown sick Smell subjects susceptible individuals Symptom target the disease therapy tissue toxicities Viral pneumonia viral proliferation virulence virus while Wuhan, China
[DOI] 10.3389/fphys.2020.00671 PMC 바로가기 [Article Type] Physiology